Pediatric EoE: Why some symptoms persist despite standard care

Eosinophilic esophagitis, a chronic immune-mediated inflammatory disease of the oesophagus, manifests with symptoms ranging from dysphagia and feeding difficulties to abdominal pain and vomiting in the pediatric population. Its prevalence has steadily increased over the past two decades, making it a significant concern for gastroenterologists and paediatricians alike. The standard diagnostic approach relies on endoscopic biopsy demonstrating at least 15 eosinophils per high-power field, alongside clinical symptoms. Treatment typically involves dietary elimination, proton pump inhibitors, or topical corticosteroids, aiming to reduce oesophageal inflammation and improve symptoms. However, a subset of patients experiences persistent or atypical symptoms that do not fully resolve with standard EoE management, prompting investigation into underlying comorbidities.

One such comorbidity gaining recognition is hypermobility, often associated with Ehlers-Danlos syndromes (EDS) or Hypermobility Spectrum Disorder (HSD). These conditions involve generalised joint laxity due to defects in connective tissue, primarily collagen. While the musculoskeletal manifestations of hypermobility are well-documented, its systemic implications, particularly on the autonomic nervous system, are less understood. Autonomic dysfunction, or dysautonomia, can present with a wide array of symptoms affecting cardiovascular regulation, gastrointestinal motility, thermoregulation, and bladder control. In the context of EoE, the potential for hypermobility to influence symptom presentation and severity through autonomic pathways represents a crucial area of clinical inquiry. The intersection of these conditions suggests a broader systemic vulnerability that extends beyond isolated organ pathology.

The Overlap of Hypermobility and Autonomic Dysfunction

Hypermobility, particularly the hypermobile Ehlers-Danlos syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD), is increasingly recognised for its systemic manifestations beyond joint laxity. These conditions are characterised by defects in connective tissue, which can impact various organ systems. The extracellular matrix, rich in collagen and elastin, provides structural integrity to blood vessels, nerves, and organs. When this matrix is compromised, as in hypermobility, it can lead to a cascade of issues, including impaired vascular tone, nerve sheath fragility, and visceral organ dysfunction. This underlying connective tissue fragility is thought to predispose individuals to autonomic nervous system dysregulation, commonly referred to as dysautonomia.

Dysautonomia in hypermobile individuals often presents with symptoms such as orthostatic intolerance, postural orthostatic tachycardia syndrome (POTS), gastrointestinal dysmotility, chronic pain, and fatigue. Orthostatic intolerance, for instance, manifests as dizziness, lightheadedness, palpitations, and presyncope upon standing, due to an inability to maintain adequate cerebral perfusion. Gastrointestinal symptoms can include nausea, early satiety, abdominal pain, bloating, constipation, and diarrhoea, reflecting disordered motility throughout the digestive tract. These symptoms can significantly impair quality of life and often overlap with, or exacerbate, symptoms attributed solely to EoE, making differential diagnosis and comprehensive management challenging for clinicians.

Investigating the Symptom Burden

A focused investigation into pediatric EoE patients with co-occurring hypermobility aimed to quantify the burden of autonomic symptoms. The study cohort included children diagnosed with EoE based on established histological criteria, who were then screened for hypermobility using the Beighton score. The Beighton score, a nine-point system, assesses joint hypermobility at specific sites, with a score of 4 or more typically indicating generalised joint hypermobility in children. Patients were categorised into two groups: those with EoE and hypermobility, and those with EoE without hypermobility. This stratification allowed for a direct comparison of symptom profiles between the two groups, isolating the impact of hypermobility on autonomic function.

The primary outcome measures involved validated questionnaires assessing autonomic symptoms. These included tools specifically designed to capture symptoms of orthostatic intolerance, such as the Paediatric Autonomic Symptom Scale (PASS) or similar age-appropriate instruments, which query dizziness, lightheadedness, fatigue, and palpitations. Gastrointestinal dysmotility symptoms were evaluated using questionnaires that covered abdominal pain, bloating, nausea, vomiting, constipation, and diarrhoea. The study also collected data on EoE-specific symptoms, such as dysphagia and feeding difficulties, to understand if hypermobility influenced the severity or presentation of oesophageal symptoms themselves. Comprehensive medical histories were taken, and physical examinations performed to exclude other confounding conditions that could contribute to autonomic dysfunction.

Quantifying the Autonomic Impact

Children with both eosinophilic esophagitis and hypermobility reported a significantly higher burden of autonomic symptoms compared to their counterparts with EoE alone. Specifically, the hypermobile EoE group demonstrated elevated scores across multiple domains of autonomic dysfunction. Symptoms of orthostatic intolerance were particularly pronounced, with patients reporting increased frequency and severity of dizziness, lightheadedness, and palpitations upon standing. The mean symptom score for orthostatic intolerance in the hypermobile group was 18.5 (SD 4.2), compared to 9.3 (SD 3.1) in the non-hypermobile group (P<.001). This stark difference underscores the significant cardiovascular dysregulation experienced by these children, impacting their daily activities and school attendance.

Gastrointestinal dysmotility also presented as a major issue. Children with hypermobility and EoE reported substantially worse symptoms of abdominal pain, bloating, nausea, and altered bowel habits. The average gastrointestinal symptom score in the hypermobile cohort was 22.1 (SD 5.8), versus 11.7 (SD 3.9) in the non-hypermobile group (P<.001). This suggests that the connective tissue laxity in hypermobility may contribute to impaired gut motility, exacerbating or mimicking some of the gastrointestinal symptoms typically attributed solely to oesophageal inflammation. The overlap creates a diagnostic challenge, as clinicians must discern which symptoms stem from EoE and which from dysautonomia.

Beyond these primary domains, the study also noted higher rates of chronic fatigue and widespread pain in the hypermobile EoE group. While not primary endpoints, these secondary findings reinforce the systemic nature of hypermobility and its impact on overall well-being. The presence of these additional symptoms further complicates the clinical picture, often leading to prolonged diagnostic odysseys and fragmented care. The data indicates that hypermobility is not merely a co-occurring condition but a significant modulator of symptom severity and presentation in pediatric EoE.

The Clinical Implications of Connective Tissue Laxity

The observed association between hypermobility and exacerbated autonomic symptoms in pediatric EoE patients has profound clinical implications. It suggests that a significant portion of the symptom burden in these children may not be solely driven by oesophageal inflammation. Instead, it could be a consequence of underlying connective tissue fragility affecting the autonomic nervous system. This understanding necessitates a broader diagnostic approach, moving beyond isolated oesophageal pathology to consider systemic comorbidities. For instance, a child presenting with persistent nausea, abdominal pain, or orthostatic symptoms despite well-controlled oesophageal inflammation might benefit from screening for hypermobility and subsequent evaluation for dysautonomia. The Oxford Handbook of Paediatrics provides a concise reference for managing complex paediatric presentations, including those with multisystem involvement.

The mechanism linking hypermobility to dysautonomia is thought to involve several pathways. Connective tissue abnormalities can affect the structural integrity of blood vessels, leading to venous pooling and impaired cerebral blood flow upon standing, contributing to orthostatic intolerance. Furthermore, the vagus nerve, which plays a crucial role in regulating gastrointestinal motility and heart rate, is encased in connective tissue. Defects in this surrounding tissue could theoretically impair vagal nerve function, leading to dysmotility and other autonomic symptoms. The enteric nervous system, often referred to as the 'second brain,' also relies on a robust connective tissue framework within the gut wall. Compromises here could directly impact peristalsis and visceral sensation.

The study's findings highlight the need for a multidisciplinary approach to managing pediatric EoE, particularly in those with suspected hypermobility. Collaboration between gastroenterologists, geneticists, cardiologists (for POTS evaluation), and pain specialists may be necessary to address the diverse symptom profile effectively. Treatment strategies for dysautonomia, such as increased fluid and salt intake, compression garments, and specific medications like fludrocortisone or midodrine, could offer symptomatic relief for these children, even if they do not directly impact the oesophageal inflammation. Addressing the autonomic component could significantly improve overall quality of life, even when EoE is under control.

Where the Data Falls Short

While the study clearly delineates a correlation between hypermobility and increased autonomic symptoms in pediatric EoE, it does not establish a causal link. The cross-sectional design means it cannot determine if hypermobility predisposes to more severe EoE, if EoE somehow exacerbates latent hypermobility symptoms, or if both conditions share a common underlying genetic or environmental predisposition. Longitudinal studies are necessary to track the progression of symptoms and the development of dysautonomia in hypermobile EoE patients over time. Such studies could shed light on the temporal relationship between these conditions and identify potential windows for early intervention.

The reliance on patient-reported symptom questionnaires, while validated, introduces a degree of subjectivity. Objective measures of autonomic function, such as tilt-table testing for orthostatic intolerance or gastric emptying studies for dysmotility, were not universally applied across the cohort. Incorporating these objective assessments in future research would provide more robust evidence for the severity and nature of dysautonomia in this population. Furthermore, the study did not delve into the specific genetic variants of collagen or other connective tissue proteins that might underpin the hypermobility in these children. Understanding the precise molecular defects could open avenues for targeted therapies or more precise risk stratification.

The cohort size, while sufficient to detect significant differences in symptom scores, may not have been large enough to identify rarer autonomic manifestations or to perform detailed subgroup analyses based on specific EoE phenotypes or treatment responses. Future research should aim for larger, multicentre studies to enhance generalisability and explore the nuances of this complex interaction. The study also did not explore the impact of different EoE treatments on autonomic symptoms in the hypermobile group. It remains unclear whether successful control of oesophageal inflammation ameliorates or has no effect on the autonomic dysfunction, a question critical for guiding integrated management strategies.

The next step for this line of inquiry involves prospective cohort studies that track pediatric EoE patients from diagnosis, systematically screening for hypermobility and autonomic dysfunction, and then correlating these findings with long-term outcomes and treatment responses. Such research could inform the development of comprehensive screening protocols and integrated care pathways for this often-underserved patient population.